¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"base ratio"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • cell color ratio
    ÀûÇ÷±¸»ö¼Òºñ
  • caliber ratio
    1. Ç÷°ü°æºñÀ² 2. ±¸°æºñÀ²
  • charge to mass ratio
    ÀüÇÏ´ëÁú·®ºñ
  • child-woman ratio
    ¸ð¾ÆºñÀ²
  • dependency ratio
    ºÎ¾çºñ
  • depth to width ratio
    ±íÀÌ´ë³Êºñºñ
  • dextrose-nitrogen ratio
    Æ÷µµ´çÁú¼Òºñ
  • dilution ratio
    Èñ¼®ºñ
  • disease odds ratio
    Áúº´±³Â÷ºñ, Áúº´½Â»êºñ
  • distribution ratio
    ºÐÆ÷ºñÀ²
  • exposure ratio
    ³ëÃâºñÀ²
  • exposure-odds ratio
    ³ëÃâ±³Â÷ºñ
  • extraction ratio
    ÃßÃâ·ü
  • fetal death ratio
    žƻç¸Áºñ
  • gyromagnetic ratio
    ÀÚ±âȸÀüºñ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • child-woman ratio
    ¸ð¾ÆºñÀ²
  • common ratio
    °øºñ
  • contrast enhancement ratio
    Á¶¿µÁõ°­ºñ
  • contrast to noise ratio
    ´ëÁ¶ÀâÀ½ºñ
  • correlation ratio
    »ó°üºñ
  • cumulative incidence ratio
    ´©Àû¹ß»ýºñ
  • cup-disc ratio
    À¯µÎÇÔ¸ôºñ
  • curative ratio
    Ä¡À¯ºñ
  • dependency ratio
    ºÎ¾çºñ
  • depth to width ratio
    ±íÀÌÆøºñÀ²
  • dextrose-nitrogen ratio
    Æ÷µµ´çÁú¼Òºñ
  • dilution ratio
    ¹±Èûºñ, Èñ¼®ºñ
  • disease odds ratio
    Áúº´±³Â÷ºñ
  • distribution ratio
    ºÐÆ÷ºñÀ²
  • exposure ratio
    ³ëÃâºñÀ²
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 9 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • inspiratory expiratory ratio
    ÈíÈ£±â´ëºñ.
  • phase ratio
    »óºñ(ßÓÝï).
  • primary sex ratio
    ÀÏÂ÷¼º ºñ(ÊÙËÛËÓ).
  • ratio
    ºñ(ËÓ).
  • ratio
    ºñ(Ýï)
  • ratio estimate
    ºñÃßÁ¤·®(ËÓÌ§ËøËâ).
  • ratio intelligence qoutient
    Áö´ÉºñÀ²Áö¼ö
  • ratio of accommodative convergence to accommodation
    Á¶ÀýÆøÁÖºñ
  • ratio of dependants
    ºÎ¾çºñ(ËÓËâËÓ).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • mendelian ratio
    ¸àµ¨·ü(¡­ëÏ).
  • mendelian ratio
    ¸àµ¨·ü(¡­ëÏ)
  • mixing water ratio
    È¥¼öºñ(ûèâ©Ýï) ¡ì¼®°í¡í.
  • monocyte lymphocyte ratio
    ´Ü±¸¸²ÇÁ±¸ºñ(ӤϹ¡­Ï¹Ýï).
  • monocyte lymphocyte ratio
    ´Ü±¸¸²ÇÁ±¸ºñ(ËÀË´?Ë´ËÓ).
  • noise ratio
    ÀâÀ½ºñ(ËöËôËÓ).
  • noise ratio
    ÀâÀ½ºñ
  • optimal proportion =o. ratio
    ÃÖÀûºñ (Ì§ËøËÓ).
  • optimal ratio
    ÃÖÀûºñ.
  • optimum ratio
    ÃÖÀûºñ
  • optimum ratio
    ÃÖÀûºñ(õÌîêÝï).
  • oxygen enhancement ratio (OER)
    »ê¼ÒÁõ°­ºñ
  • oxygen enhancement ratio =OER
    »ê¼ÒÈ¿°úÁõ°­·ü(¡­üùÍýñòË­ëÒ).
  • phase ratio
    »óºñ(ßÓÝï).
  • primary sex ratio
    ÀÏÂ÷¼º ºñ(ÊÙËÛËÓ).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • base pairing
    "¿°±â(ç¤Ðñ) ¦Áþ±â, ¿°±â ¦Áö¿ò"
  • base-pairing rules
    ¿°±â ¦Áþ±â ±ÔÄ¢(ЮöÎ)
  • base-pair substitution
    ¿°±â¦ ġȯ(öÇüµ)
  • base sequence
    ¿°±â¼­¿­(ç¤ÐñßíÖª)
  • base specificity
    ¿°±âƯÀ̼º(ç¤Ðñ÷åì¶àõ)
  • base stacking
    ¿°±â(ç¤Ðñ) ½×ÀÓ
  • base substitution
    ¿°±âġȯ(ç¤ÐñöÇüµ)
  • Bronsted base
    ºê·Ð½ºÅ×µå ¿°±â(ç¤Ðñ)
  • complementary base pairing
    »óº¸¼º(ßÓÜÍàõ) ¿°±â(ç¤Ðñ) ¦Áþ±â
  • complementary base sequence
    »óº¸¼º ¿°±â¼­¿­(ßÓÜÍàõç¤ÐñßíÖª)
  • concerted acid-base catalysis
    Çùµ¿ »ê¿°±â Ã˸Å(úðÔÒß«ç¤ÐñõºØÚ)
  • conjugate acid-base pair
    ¦ÁöÀº »ê¿°±â½Ö(ß«ç¤Ðñäª)
  • general acid-base catalysis
    ÀϹÝ(ìéÚõ) »ê-¿°±â Ã˸Å(ß«-ç¤ÐñõºØÚ)ÀÛ¿ë
  • Hoogsten base pairs
    ÈŽºÆ¾ ¿°±â ½Ö(äª)
  • Lewis acid-base catalysis
    ·çÀ̽º »ê-¿°±â(ß«.ç¤Ðñ) Ã˸ÅÀÛ¿ë(ç¤Ðñ õºØÚÚãëë)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
BE   1) Bacterial Endocarditis
  2) Base Excess
  3) Below the Elbo...
bp base pair; ¿°±â½Ö
JVP [POMD P 49 - 52]
  1) Jugular Vein Pressure
  2) Jugular Venous Pulse
...
AIDSDRUGS clinical trials of acquired immunodeficiency drugs [MEDLARS data base]
AIDSLINE on-line information on acquired immunodeficiency syndrome [MEDLARS data base]
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
Mb mega-base pairs
PSB protonated Schiff base
APC SR APC sensitivity ratio
AOR Adjusted Odds Ratio
ACCR Amylase-creatinine clearance ratio
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • buffer base
    ¿ÏÃæ ¿°±â
  • cement base
    ½Ã¸àÆ® ÀÌÀåÃþ, ½Ã¸àÆ® º£À̽º
    Çü¼ºµÈ ¿Íµ¿ÀÌ ±í¾î¼­ Ä¡¼ö¸¦ º¸È£Çϰųª, ÃæÀü¹°ÀÇ ¾ç°ú Å©±â¸¦ °¨¼Ò½Ã۰í, ÇÔ¸ô ºÎÀ§¸¦ ¾ø¾Ö±â À§ÇÏ¿© ½Ã¸àÆ®·Î Àú¸é¿¡ ä¿ì´Â °Í.
  • complementary base pair
    »óº¸¼º ¿°±â½Ö
  • cranial base
    µÎ°³±âÀúºÎ, µÎ°³Àú
  • dental base cement
    Ä¡°ú¿ë ÀÌÀå ½Ã¸àÆ®
    Ä¡¼ö¸¦ Àý¿¬½Ã۱â À§ÇØ, Çü¼ºµÈ ¿Íµ¿ÀÇ ½ÉºÎ¿¡ À§Ä¡½ÃŲ ½Ã¸àÆ®ÀÇ Àý¿¬Ãþ.
  • denture base esthetics
    ÀÇÄ¡ ½É¹Ì¼º
    ÀÇÄ¡ Á¦ÀÛ¿¡ À־ °¡Àå Áß¿äÇÑ ¿ä¼ÒÀÇ Çϳª·Î½á ÀûÇÕÇÑ Ã¤»ö, ¿ÜÇü°ú Ä¡Àº¿¡ ÇØ´çÇÏ´Â ºÎÀ§ÀÇ ÇüÅ µîÀÌ ÀÚ¿¬½º·´°í Á¶È­µÇµµ·Ï ÇÏ´Â ¹ÌÀû ¿ä¼ÒÀÌ´Ù.
  • dye base
    »ö¼Ò±â
  • fixed base
    °íÁ¤ ¿°±â
  • fracture of base of skull
    µÎ°³Àú °ñÀý
  • intermediary base
    Áß°£ ÀÌÀåÀç
  • jawcranial base relationship
    ¾Ç°ñ µÎ°³ÀúÀÇ °ü°è
  • metal base
    ±Ý¼Ó»ó
    ÀÇÄ¡¿¡ À־ ÀϺΠ¶Ç´Â ÀüºÎ°¡ ±Ý¼ÓÀ¸·Î µÇ¾îÀÖ´Â ºÎºÐÀ» ¶æÇÏ¸ç ¶§·Î´Â ÀÇÄ¡»ó Àç·á³ª ÀΰøÄ¡¾Æ¿Í ±â°èÀûÀ¸·Î °áÇյǾî Áö±âµµ ÇÑ´Ù.
  • model base
    ¸ðÇü Àú¸é
    ¸ðÇüÀÇ ¹Ø¸é.
  • monoacidic base
    ÀÏ»ê ¿°±â
  • narrow base
    Á¼Àº ±âÀúºÎ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
odds ratio <epidemiology> A comparison of the presence of a risk factor for disease in a sample of diseased subjects and non diseased controls. The number of people with disease who were exposed to a risk factor ( I.e. ) over those with disease who were not exposed ( Io ) divided by those without disease who were exposed ( Ne ) over those without who were not exposed ( No ). Thus OR=(I.e./Io)/(Ne/No)= I.e. No / Io Ne. This measure should be used for case control studies where we retrospectively look at risks in those with and without disease. Also known as exposure odds ratio.
(05 Dec 1998)
therapeutic ratio The ratio of the maximally tolerated dose of a drug to the minimal curative or effective dose; LD50 divided by ED50.
(05 Mar 2000)
tritium-breeding ratio <radiobiology> The amount of tritium generated by the breeding blanket of a D-T fusion reactor, divided by the amount of tritium burned in the reactor. A tritium breeding ration greater than unity is necessary for self-sufficient fueling.
(09 Oct 1997)
turn down ratio The lowest load at which a boiler will operate efficiently as compared to the boiler's maximum design load.
(05 Dec 1998)
exposure odds ratio <epidemiology> See Odds ratio.
(05 Dec 1998)
extraction ratio The fraction of a substance removed from the blood flowing through the kidney; it is calculated from the formula (A -V)/A, where A and V, respectively, are the concentrations of the substance in arterial and renal venous plasma.
(05 Mar 2000)
K:A ratio <abbreviation> Ketogenic-antiketogenic ratio.
(05 Mar 2000)
ketogenic-antiketogenic ratio The proportion between substances that form ketones in the body and those that form d-glucose.
(05 Mar 2000)
zeta sedimentation ratio The ratio of the zetacrit to the haematocrit, normally 0.41 to 0.54 (41 to 54%); it is a sensitive indicator of the erythrocyte sedimentation rate (ESR) and, unlike the latter, is unaffected by anaemia, which tends to elevate the ESR.
(05 Mar 2000)
fertility ratio A measure of the fertility of a population based on the female population in the child-bearing age-group, defined as ages 15-49 years.
(05 Mar 2000)
flux ratio The ratio of the two unidirectional fluxes through a particular boundary layer or membrane.
(05 Mar 2000)
lecithin/sphingomyelin ratio A ratio used to determine foetal pulmonary maturity, found by testing the amniotic fluid; when the lungs are mature, lecithin exceeds sphingomyelin by 2 to 1.
(05 Mar 2000)
functional terminal innervation ratio The number of muscle fibres divided by the number of axons that innervate them.
(05 Mar 2000)
low aspect ratio <physics> An aspect ratio for a torus that is small (minor radius is almost as big as major radius).
There are many fusion devices which are designed to have a low aspect ratio. Such devices look more like tractor tires than bicycle tires, as toruses go. There are reasons to believe that low aspect ratio devices will offer some advantages for a fusion reactor. Usually, ease of theoretical and/or numerical analysis is not one of these advantages.
(16 Mar 1998)
L/S ratio <abbreviation> Lecithin/sphingomyelin ratio.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
ÅëÇÕ°Ë»ö ¿Ï·á